- Article
Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
- Ulrich Wuellner,
- Kristina Klupsch,
- Fabian Buller,
- Isabella Attinger-Toller,
- Roger Santimaria,
- Irene Zbinden,
- Patricia Henne,
- Dragan Grabulovski,
- Julian Bertschinger and
- Simon Brack
CD3 bispecific therapies retargeting T cells to tumors have recently demonstrated striking activity in patients. Several CD3 bispecific antibodies directed against various tumor targets are currently being investigated in the clinic across different...

